TICKERNERD
Menu
MLYSMLYSHealthcare · Biotechnology

MLYS Stock Forecast: Mineralys Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$28
−0.21% on the day

The 10 Wall Street analysts covering Mineralys Therapeutics, Inc. hold a median 12-month price target of $52 — +84.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 5 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.5B
Ticker Nerd rank
25 / 100
Median analyst target
$52
Analysts covering
10
Revenue$0.0
Operating income−$246.0M
Net income−$241.1M
Free cash flow−$32.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+10.2%
1M
+6.5%
YTD
−22.3%
1Y
−14.8%
From 52W high
−40.4%
From 52W low
+25.4%
$23
$47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MLYS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Mineralys Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
72
Value
55
Accruals
52
Quality
46
Volatility
44
Revisions
34
Size
33
Growth
26
Issuance
8

Momentum (72): The shares have been drifting up relative to others.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MLYS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MLYS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26MLYSHigh $56Median $52Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $30Median $52High $56

The green dot is the last close — the median target sits +84.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Apr 2026TD CowenInitiatesBuy—
27 Apr 2026TD CowenInitiatesBuy—
13 Mar 2026B of A SecuritiesMaintainsBuy—
19 Dec 2025StifelMaintainsBuy—
12 Nov 2025HC Wainwright & Co.MaintainsBuy—
11 Nov 2025Wells FargoMaintainsOverweight—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
11 Sept 2025Wells FargoMaintainsOverweight—
9 Sept 2025Goldman SachsMaintainsBuy—
8 Sept 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025JefferiesMaintainsHold—
28 Aug 2025B of A SecuritiesMaintainsBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
17 June 2025HC Wainwright & Co.ReiteratesBuy—
11 June 2025JefferiesInitiatesHold—
13 May 2025HC Wainwright & Co.ReiteratesBuy—
2 Apr 2025HC Wainwright & Co.MaintainsBuy—
10 Mar 2025HC Wainwright & Co.ReiteratesBuy—
24 Feb 2025GuggenheimReiteratesBuy—
13 Feb 2025Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MLYS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MLYS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Mineralys Therapeutics, Inc. returned −14.8% against +20.0% for the S&P 500, dividends included.

MLYS vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26MLYSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MLYS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
6
Fundamentals

Mineralys Therapeutics, Inc. (MLYS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.3×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
4.5×

Cheaper than 23% of US stocks

EV / EBITDA
−5.2×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−80.9%

Higher than 16% of US stocks

Return on assets
−46.2%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Mineralys Therapeutics, Inc. (MLYS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Mineralys Therapeutics, Inc. has a market value of $2.5B and an enterprise value of $1.9B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$349.6M.

  • Diluted earnings per share, trailing twelve months: $−4.24.

  • Free cash flow in the twelve months to 30 June 2026: −$138.8M.

  • Shares outstanding: 88.4M.

  • Trailing P/E: −12.3×; forward P/E: −11.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Mineralys Therapeutics, Inc. employs 76 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

MLYS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MLYSMineralys Therapeutics, Inc.$2.5B
25
NKTRNektar Therapeutics$2.5B
51
PGENPrecigen, Inc.$2.5B
82
VERAVera Therapeutics, Inc.$2.5B
29
TRVITrevi Therapeutics, Inc.$2.4B
53
VRDNViridian Therapeutics, Inc.$2.5B
45
PHVSPharvaris NV$2.4B
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Mineralys Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MLYS news & analysis

Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision

Seeking Alpha · 3 Sept 2026positive

The article upgrades Mineralys Therapeutics to Buy, citing lorundrostat's anticipated FDA approval in December and expectations of a strong commercial launch. It notes MLYS's focused strategy and robust funding position it to capture significant hypertension market share despite AstraZeneca's Baxfendy having first-mover advantage.

Why it matters — A MLYS watcher would care because the piece highlights lorundrostat's competitive efficacy and safety profile, its potential for blockbuster revenues, and the possibility of future label expansion beyond blood pressure reduction.

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

GlobeNewsWire · 26 Aug 2026neutral

Mineralys Therapeutics announced that its management will participate in the Wells Fargo 21st Annual Healthcare Conference, to be held in Boston from September 8-10, 2026. The company is a biopharmaceutical firm developing treatments for hypertension and aldosterone-related outcomes in conditions such as chronic kidney disease and obstructive sleep apnea.

Why it matters — Mineralys watchers may view the conference appearance as a chance for the company's management to present and discuss its pipeline with the investment community.

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 13 Aug 2026neutral

Mineralys Therapeutics granted an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares to its newly appointed Chief Medical Officer, Dr. Terry Ferguson, on August 10, 2026. The award was approved by a majority of the independent directors of the Company's Board of Directors under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The inducement award provides information on executive compensation for a newly hired senior leader, which MLYS watchers may consider when evaluating the company's leadership incentives and governance practices.

Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Seeking Alpha published the transcript of Mineralys Therapeutics' Q2 2026 earnings call, covering the company's second-quarter results and management discussion. The item is a record of the earnings call proceedings.

Why it matters — A MLYS watcher would care because the transcript provides direct, unedited access to management commentary and operational detail from the company's latest earnings call.

Mineralys Therapeutics Q2 Earnings Call Highlights

MarketBeat · 11 Aug 2026neutral

Mineralys Therapeutics reported a wider second-quarter loss, driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp. The company said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date.

Why it matters — MLYS watchers would care because the wider loss reflects a major strategic deal with Tanabe Pharma while the company advances lorundrostat toward its December 22 PDUFA target date and commercial launch preparations.

FAQ

Frequently asked questions about MLYS stock

What is the MLYS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Mineralys Therapeutics, Inc. have a median 12-month price target of $52, with estimates ranging from $30 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MLYS stock a buy right now?

Of the 10 analysts covering Mineralys Therapeutics, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mineralys Therapeutics, Inc. 25 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MLYS?

As at 5 Sept 2026, Mineralys Therapeutics, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (72 of 100).

Will MLYS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +84.3% from the last close, and Ticker Nerd's factor model ranks Mineralys Therapeutics, Inc. 25 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MLYS stock forecast for 2030?

No analyst covering Mineralys Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MLYS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $56 over the next 12 months.

How has MLYS stock performed over the past year?

Mineralys Therapeutics, Inc. returned -14.8% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Mineralys Therapeutics, Inc. do?

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone.

What is the latest news on MLYS?

The most recent item we track (Seeking Alpha, 3 Sept 2026): "Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision". The article upgrades Mineralys Therapeutics to Buy, citing lorundrostat's anticipated FDA approval in December and expectations of a strong commercial launch. It notes MLYS's focused strategy and robust funding position it to capture significant hypertension market share despite AstraZeneca's Baxfendy having first-mover advantage.

Company

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor being studied for cardiorenal conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea. Mineralys Therapeutics concentrates on the treatment of hypertension and related comorbidities, aiming to address patients who do not respond adequately to existing therapies. The company operates as a development-stage drugmaker with a pipeline centered on aldosterone-targeted treatment, combining clinical research, regulatory activity, and outsourced manufacturing and trial operations. Based in Radnor, Pennsylvania, Mineralys Therapeutics plays a specialized role in the biopharmaceutical market by advancing therapies for cardiometabolic and renal diseases with a focus on precision targeting of hormone-driven pathways.

CEO Dr. Jon Congleton · 76 employees · United States · https://mineralystx.com